Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RuCat

Financiado

New Horizons in C H Activation the Real World Molecules Challenge

A 2018 joint report from pharma identified organic synthesis as one of the major bottlenecks in drug discovery today. In the highly competitive discovery environments, only fast-to-synthesise molecules are targeted, based mostly o... ver más

28/02/2026

UNIVERSITY OF MANC...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE UNIVERSITY OF MANCHESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-04-04

ERC-2018-ADG: ERC Advanced Grant

I+D

Cerrada hace 6 años

0% 100% 100%

2 Participantes

UNIVERSITY OF MANCHESTER

2.50M€ | Lider

GESTORA CATALANA DE RESIDUOS

404.31K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 82 meses Fecha Inicio: 2019-04-04
Fecha Fin: 2026-02-28

Líder del proyecto

THE UNIVERSITY OF MANCHESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto A 2018 joint report from pharma identified organic synthesis as one of the major bottlenecks in drug discovery today. In the highly competitive discovery environments, only fast-to-synthesise molecules are targeted, based mostly on five well-tested and proven synthetic methods. This approach has led to only a small portion of the chemical shape space being explored over the last decades and has been partly blamed for the recent low success rates in new drug development. The report emphasises the need for ideal tools such as late stage functionalisation, which would allow simply replacing any C‒H bond in a bioactive molecule with any desired functionality, thus greatly accelerating the synthesis of new candidates from a lead compound. However, the field of C‒H activation is significantly behind in achieving this aim: most biologically active molecules contain several polar and/or delicate functionalities (‘real world’ molecules), whereas most C‒H activation methods use harsh conditions, incompatible with delicate groups, and catalysts that tend to poison in the presence of polar groups. This ERC Advanced Grant addresses this major challenge by building a new tool-set of ruthenium catalysts that will finally be able to deliver late stage functionalisation on ‘real world’ molecules, thus allowing a new dawn for development not only of new drugs, but also of agrochemicals, aromatic based organic materials and associated areas. The project builds on a recent key mechanistic breakthrough by the PI's group on the operation of Ru-catalysts (Nature Chemistry 2018) that reveals a completely different pathway to catalyst design from that followed in the field in the last two decades. This new class of catalysts presents unprecedented high reactivity and compatibility with sensitive ‘real world’ molecules. The PI is in a unique position to capitalize on this discovery and lead the way towards global late stage functionalisation of ‘real world’ molecules.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores